HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic ...

The Business Research Company's Memantine HCl Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034 Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed On ...

Forest Laboratories announced that it has submitted a New Drug Application (NDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER), a receptor antagonist and donepezil HCl, ...

Actavis and Adamas announced that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric (memantine HCl extended-release and donepezil HCl) capsules for the ...

DUBLIN, May 22, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that a panel of the U.S. Court of Appeals for the Second Circuit has issued a ruling upholding a December 15, 2014 ...

NEW YORK, Feb. 5 -- Forest Laboratories, Inc. (NYSE: FRX - News) today announced preliminary results of a Phase III study of memantine HCl (currently marketed as Namenda®, a twice-daily immediate- ...

Actavis and Adamas Pharmaceuticals Inc announced that the US Food and Drug Administration (US FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine ...

Forest Laboratories hopes to win approval for a blend of memantine HCl extended release, and donepezil HCl. Forest Laboratories (NYSE: FRX) has taken a big step toward approval for a combination ...